Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

The Heart of Abbott Laboratories (ABT)’s Future

It’s not an easy time to be a health care investor.

Between the patent cliff, taxes, and Europe’s meltdown, there’s enough information and legislation swirling about to keep concerned shareholders up for days. Perhaps the biggest trend of a changing industry has come from spinoffs, however: Abbott Laboratories (NYSE:ABT) made waves in health care by offloading its pharmaceutical business, and other companies have joined in the spinoff game by dumping unwanted divisions.

With some of the biggest players in the industry shaking things up, investors are left wondering what to make of companies they’ve invested in — and what to expect from the future. Let’s take a look at Abbott Labs and one key area that could power the growth of tomorrow for this radically changed company: its vascular business.

Abbott Laboratories (NYSE:ABT)Playing with heart
Growth’s a tough thing for Abbott these days. New pharmaceuticals offer instant revenue-generating power when they hit the market, and blockbuster drugs can fuel a company for a long time — Abbott’s spun-off pharmaceutical branch, AbbVie Inc (NYSE:ABBV), relied on a single drug for over half of its 2012 sales, for instance. Abbott can no longer rely on such lucrative avenues for growth in its post-pharmaceutical life.

So, what’s so promising about its vascular business? At first look, the business isn’t particularly eye-opening. It generated 3.4% operational sales growth after excluding one-time items in 2012, hardly enough to wow investors. However, around half of those sales came from a single product line — Abbott’s family of Xience drug-eluting stents. The Xience line has been the top-selling stent family for several years, exceeding yearly revenue of $1 billion every year since 2009.

The Xience family alone cranked out $1.6 billion in sales during 2012, with massive growth abroad. While the American market may be slowing for stents, this line should keep carrying Abbott forward — and the company has a new generation of stent ready to emerge to boot.

Promising picks
Abbott recently picked up FDA approval for another next-generation line of Xience, the Xpedition. It’s another success for this tried-and-true product family, but Abbott’s Absorb stent, currently in clinical trials in the U.S., represents the future.

Absorb is a bioresorbable stent that fully absorbs into the bloodstream — a trick that competitors in this space haven’t yet caught up to. It launched in Europe last year, and Abbott has plans to file for regulatory approval in the U.S. by 2015. There’s limited competition for something like the Absorb, with only Boston Scientific Corporation (NYSE:BSX) pushing into the next generation of stents right now with its Synergy stent.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.